Search results
Springbok Analytics Announces Phase 1 Clinical Trial Evaluating Clenbuterol as FSHD Treatment
The Tomahawk· 4 days agoSpringbok Analytics (www.springbokanalytics.com), a life sciences muscle analytics company, announced today its participation in a Phase 1 Clinical Trial to evaluate safe dosage for clenbuterol ...
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater...
Morningstar· 5 days agoAvidity plans to accelerate initiation of registrational cohorts in the FORTITUDE™ study.
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
FierceBiotech· 5 days agoAvidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to...
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Zacks· 4 days agoInitial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Investor's Business Daily· 4 days agoThe top-rated biotech stock soared to a record high. The company is working on a treatment called...
Avidity Biosciences to Participate in Upcoming Investor Conference
KPVI· 2 days agoA live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https ...